• Ordered DNA Nanostructures Enhance Enzymatic DNA Synthesis

  2026-06-03

  This study demonstrates that highly ordered tetrahedral DNA nanostructures (TDNs) can dramatically improve enzymatic oligonucleotide synthesis (EOS), overcoming key limitations of primer accessibility and spatial hindrance. The findings open new avenues for accurate, high-yield DNA synthesis, especially in applications such as DNA data storage.

• Cefazedone (Refosporen): Applied Protocols for Antibacterial

  2026-06-03

  Cefazedone (Refosporen) stands out as a β-lactamase-resistant, first-generation cephalosporin with robust efficacy for both Gram-positive and Gram-negative bacterial infections. This guide delivers actionable experimental workflows, troubleshooting insights, and data-backed protocol enhancements for maximizing Cefazedone’s translational research value.

• Angiotensin 1/2 (2-7): Bridging Cardiovascular and Viral Res

  2026-06-02

  Explore how Angiotensin 1/2 (2-7) is reshaping translational research across cardiovascular and infectious disease domains. This article delivers mechanistic insights, protocol guidance, and critical analysis of emerging evidence—positioning APExBIO’s high-purity peptide as a cornerstone for next-generation studies in blood pressure regulation and viral-host interaction.

• A-1331852: Advanced BCL-XL Inhibitor Workflows for Cancer Re

  2026-06-02

  A-1331852 stands out as a highly selective BCL-XL inhibitor, enabling precise apoptosis induction in cancer models with robust potency and workflow flexibility. This article details state-of-the-art protocols, troubleshooting insights, and real-world applications, drawing on recent breakthroughs in targeting BCL-2 family protein inhibition—especially for resistant and stem-like tumor subpopulations.

• Angiotensin II and Vascular Senescence: Mechanisms and Pathw

  2026-06-01

  This thought-leadership article synthesizes the latest mechanistic insights on Angiotensin II—especially its role in endothelial dysfunction and vascular aging—with practical guidance for translational researchers. Drawing on recent evidence, including the regulatory role of mitofusin 2 in Ang II-induced endothelial senescence, the article charts a strategic path for advancing vascular smooth muscle cell hypertrophy and hypertension mechanism studies. It also positions APExBIO’s Angiotensin II as a validated, reproducible research tool, while contextualizing its use within evolving experimental and clinical frameworks.

• Hemagglutinin mRNA Vaccine Protects Dairy Cows Against H5N1

  2026-06-01

  This study demonstrates the robust, long-lasting protection of a hemagglutinin-based mRNA vaccine against H5N1 influenza in lactating dairy cows. The work establishes a scientific foundation for mRNA vaccination strategies in livestock, with important implications for animal and public health.

• Berberine Suppresses SASP Inflammation via RXRα/PPARγ/NEDD4

  2026-05-31

  The referenced study uncovers how berberine attenuates senescence-associated secretory phenotype (SASP)-driven inflammation in atherosclerosis by engaging the RXRα/PPARγ/NEDD4 pathway in macrophage-derived foam cells. These findings elucidate a mechanistic basis for anti-inflammatory interventions in vascular aging, informing future research on the modulation of PPARγ signaling.

• Carvedilol Phosphate in Precision Hepatic IRI Modeling: Adva

  2026-05-30

  Explore how Carvedilol Phosphate, a non-selective beta blocker, enables more precise hepatic ischemia–reperfusion injury (IRI) modeling and macrophage polarization studies. This article uniquely integrates assay optimization, molecular pathway insights, and practical protocol guidance for advanced cardiovascular pharmacology research.

• Amitriptyline HCl: Technical Guidance for Neuropharmacology

  2026-05-29

  Amitriptyline HCl (SKU B2231) addresses critical needs in neuropharmacology research by enabling precise neurotransmitter receptor modulation and mechanistic studies of serotonin and norepinephrine pathways. It is best suited for short-term experimental workflows requiring high-purity, well-characterized small molecule inhibitors and is not recommended for protocols demanding long-term solution stability or unsupported mechanistic extrapolations.

• One-step TUNEL Cy5 Apoptosis Detection Kit: Mechanism & Appl

  2026-05-29

  The One-step TUNEL Cy5 Apoptosis Detection Kit enables sensitive, Cy5-based detection of DNA fragmentation during apoptosis. This article details the kit’s mechanism, protocol parameters, and evidence, outlining its value in apoptosis assay workflows for tissue sections and cultured cells.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Interactio

  2026-05-28

  This study reveals that naturally occurring angiotensin peptide fragments, including N-terminally truncated forms like Angiotensin 1/2 (2-7), substantially enhance the binding of the SARS-CoV-2 spike protein to the host receptor AXL. These findings offer new mechanistic insights into how components of the renin-angiotensin system may influence viral entry and pathogenesis, with implications for both cardiovascular and infectious disease research.

• BMP4-GPX4 Axis Reduces Ferroptosis in Glaucoma Stem Cell Mod

  2026-05-28

  This study reveals that activation of the BMP4-GPX4 pathway protects retinal ganglion cells from ferroptosis and supports their differentiation following retinal stem cell transplantation in glaucoma with high intraocular pressure. These findings offer a mechanistically supported strategy for improving cell therapy outcomes in neurodegenerative ocular disease.

• Stiripentol: LDH Inhibition Redefining Epilepsy & Immunometa

  2026-05-27

  Explore Stiripentol’s mechanistic edge as an LDH inhibitor in modulating astrocyte-neuron lactate shuttling, with strategic insights for translational epilepsy and immunometabolic research. This article synthesizes foundational biology, protocol strategy, and next-gen outlooks, offering a bridge between neuroepigenetics and tumor immunology.

• Latrunculin A: Reversible Inhibitor of Actin Assembly in Res

  2026-05-27

  Latrunculin A is a potent, reversible inhibitor of actin assembly, enabling rapid, controlled disruption of the actin cytoskeleton in vitro and in living cells. It is widely used to dissect cytoskeletal regulation, cell morphology, and motility, especially in tumor and virology models. APExBIO supplies Latrunculin A for scientific research use with validated protocols.

• Angiotensin 1/2 (2-7) Peptide: Applied Workflows & Advanced

  2026-05-26

  Angiotensin 1/2 (2-7) empowers researchers to dissect vasoconstrictor signaling and blood pressure regulation with unmatched purity and flexibility. Explore its integration into cardiovascular and viral entry models, protocol optimization, and troubleshooting—anchored by the latest cross-domain discoveries.

16212 records 1/1081 page Next 12345 下5页 Last page